Patrys Limited · ASX:PAB
Patrys — Investor Presentation (June 2020)
35 slides from Patrys's investor presentation, Jun 18, 2020
Slide 1: Investor Presentation June 2020
INVESTOR PRESENTATION June 2020 Private & Confidential 1
Slide 2: Safe Harbour Statement
Safe Harbour Statement The following material is for general information purposes only and is not to be relied upon for the making of an investment decision. Any investment in Patrys Limited ACN 123 055 363 (Patrys) is subject to investment risk including the possibility of loss of capital invested
Slide 3: Investment highlights
Investment highlights Novel Developing a first-in-class, synthetically lethal, DNA-binding molecule with lead asset the potential to change the oncology landscape Platform Tumor-agnostic targeting of cancers with multiple treatment approaches, technology with potential synergistic benefits with exis
Slide 4: Near and mid term de-risking milestones and value drivers
Near and mid term de-risking milestones and value drivers Initiation of non-GLP toxicology and pharmacokinetic studies Q3 2020 Expansion of Deoxymab platform applications (eg nanoparticles) Q3 2020 Completion of stable cell line development Q4 2020 Initiation of GMP production and formulation progra
Slide 5: Financial overview
Financial overview Overview Share price performance (6 months) Trading information Share price ($) Volume (m) 0.04 16 Share price (17-Jun-20) A$0.014 52 week low / high A$0.012 /A$0.029 Shares outstanding1 1.073bn 0.03 12 Market capitalisation A$15.0m Net cash (31-Mar-20) A$4.74m 0.02 8 0.01 4 Top s
Slide 6: Board of Directors has a wealth of experience in development and deals
Board of Directors has a wealth of experience in development and deals John Read - Non-Executive Chairman • Experienced Chairman and Director in public, private and government organisations • Extensive career in venture capital, private equity and commercialisation • Former Chairman of CVC Limited (
Slide 7: Scientific Advisory Board members have invented and progressed multiple assets
Scientific Advisory Board members have invented and progressed multiple assets Dr Allen Ebens • PhD at UCLA and a Post-Doc at UCSF • 5 years with Exelixis in the Discovery Biology group • 11 years at Genentech in the Research Oncology working from concept to clinic across multiple therapeutic platfo
Slide 8: The How
THE HOW A closer look at the science 8
Slide 9: PAT-DX1 – a new approach to the fight against cancer
PAT-DX1 – a new approach to the fight against cancer PAT-DX1 is tumour agnostic and can cross the blood brain barrier, meaning development opportunities for a range of challenging cancers. PAT-DX1 is synthetically lethal as a single agent and synergistic with other therapies PAT-DX1 PAT-DX1 PAT-DX1-
Slide 10: Synthetic lethality is tumour agnostic and transforms cancer treatment
Synthetic lethality is tumour agnostic and transforms cancer treatment New paradigm, kills cancer cells but spares healthy cells deficient in DNA repair Diminishes cancer cells’ ability to repair themselves – blocking action of DDR enzymes, leading to cancer cell death Selectively toxic to cance
Slide 11: PAT-DX1 has a novel mechanism of action, killing cancer cells via synthetic lethality
PAT-DX1 has a novel mechanism of action, killing cancer cells via synthetic lethality and crosses the blood brain barrier Preferentially localises to tumours Tumour cells release ‘clouds’ of extracellular DNA PAT-DX1 is specifically attracted to extracellular DNA from dying cancer cells Transpor
Slide 12: PAT-DX1 synthetic lethality shown in a range of cancer cell lines
PAT-DX1 synthetic lethality has been shown in a range of cancer cells lines Model Cell lines with DDR deficiency + - Ovarian cancer in vitro x ✓ Colon cancer in vitro x ✓ Pancreatic cancer in vitro ✓ Pancreatic cancer in vitro ✓ GBM in vitro x ✓ GBM in vivo ✓ ✓ Causes cancer cell death x No effect o
Slide 13: PAT-DX1 suppressed breast cancer metastases and increased survival in a mouse model
PAT-DX1 suppressed growth of breast cancer metastases and increased survival in a mouse model Suppressed brain metastases Significantly increased survival -93% +86% PAT-DX1 Control PAT-DX1 Control treated treated After 4 weeks of treatment, treated mice showed 93% PAT-DX1 treatment significantly imp
Slide 14: PAT-DX1 enhances the efficacy of low dose radiation in an aggressive GBM model
PAT-DX1 enhances the efficacy of low dose radiation in an aggressive model of GBM Supressed GBM tumor growth Significantly increased survival 93% 87% 71% 52% 41% 24% Low dose PAT-DX1 PAT-DX1 + Low dose PAT-DX1 PAT-DX1 + radiation low dose radiation low dose radiation radiation After 2 weeks, treatme
Slide 15: Commercial Opportunity
COMMERCIAL OPPORTUNITY PAT-DX1 and the Deoxymab platform 15
Slide 16: Patrys is tackling cancer with a transformative new paradigm
Patrys is tackling cancer with a transformative new paradigm that could significantly alter the oncology landscape Key ‘pillars’ of cancer care A transformative approach Antibodies (Abs or mAbs) Target and kill cancer cells, with fewer side effects than small molecules Molecular targeted Surgery the
Slide 17: Development opportunities in CNS cancers and CNS metastases
Development opportunities in CNS cancers and CNS metastases • GBM and TNBC brain metastases US incidence of 32k1 • High incidence of DDR mutations and PTEN loss in brain tumors and metastases make these attractive targets • PTEN lost in 30-40% of primary GBM • PTEN loss associated with brain metasta
Slide 18: Development opportunities in systemic DDR deficient tumours
Development opportunities in systemic DDR deficient tumours Cancer incidence rates DDR mutation Opportunity (US cases p.a.)1 rates2 size 271k 16% 43k Breast Pancreatic 57k 15% 9k Ovarian 23k 20% 5k Endometerial 62k 34% 21k Colon 101k 15% 15k 1. American Cancer Society - Cancer Facts & Figures 2019 2
Slide 19: Broader platform applications including nanoparticle conjugation
Beyond the immediate opportunities for PAT-DX1 lie broader platform applications including nanoparticle conjugation PAT-DX1-NP (PLGA) supresses tumour growth PAT-DX1-NPs (PLGA) localize to metastases PAT-DX1m-NPDOX 3E10en/DOX-NPs Free NPs PAT-DX1-NPs 1500 3E10en-NPs PAT-DX1m-NP Significant reduction
Slide 20: Why Now?
WHY NOW? Growing interest 20
Slide 21: Increased awareness reflected in grants and collaborations
Increased awareness of the potential of PAT-DX1 and the broader platform technology reflected in grants and collaborations • R01 grant @ Yale: “Targeting Glioblastoma with a Nuclear- Penetrating Anti-DNA Autoantibody” (US$1.83m) • BCRP grant @ Yale: “Targeting Breast Cancer Brain Metastases with an
Slide 22: Significant upside value underpinned by recent pre-clinical deals
Significant upside value for Patrys underpinned by recent significant pre-clinical deals executed for antibody and synthetic lethality assets Recent pre-clinical transactions (licensing, asset and corporate)1 US$4,000m US$4,000m US$3,065m US$2,070m US$1,700m US$1,076m US$1,200m US$600m US$269m Deal
Slide 23: Active intellectual property strategy in place to protect key assets
Active intellectual property strategy in place to protect key assets Patrys’ Deoxymab patent portfolio1 Deoxymab patent portfolio 10 Active patent families 5 Granted patents2 19 Patent applications pending1 IP protection granted IP protection pending Patrys’ patent portfolio is targeted at major jur
Slide 24: Development timelines
Development timelines CY20 CY21 2Q 3Q 4Q 1H 2H Additional animal models PK and Non- GLP toxicology IND-enabling Expression and purification, including full IgG File IND activities for (PAT-DX3) (Aust HREA) PAT-DX1 GMP production and formulation Complete cell line GLP toxicology development Conjugati
Slide 25: Looking Ahead
Looking Ahead Initiation of non-GLP toxicology and pharmacokinetic studies Q3 2020 Expansion of Deoxymab platform applications (eg nanoparticles) Q3 2020 Completion of stable cell line development Q4 2020 Initiation of GMP production and formulation program Q1 2021 Initiation of GLP toxicology studi
Slide 26: Summary
Summary Improve patient Better tolerated Broad anti- Improve existing outcomes treatments cancer potential treatments PAT-DX1 targets both Coupling PAT-DX1 with low- PAT-DX1 has demonstrated The possibility to combine primary and metastatic dose radiation could allow therapeutic potential in a PAT-D
Slide 27: Risk factors
Risk factors 27
Slide 28: Key Risks
Key Risks • Investment in the Company involves risks that may be higher than the risks associated with an investment in other companies. The shares to be issued under the Rights Issue and the Share Top Up Facility carry no guarantee with respect to the payment of dividends, returns of capital or the
Slide 29: Specific Risks - i
Specific Risks - i Innovative The Company's product range includes candidates that are in pre-clinical development and technological need to be further tested before they can progress to human clinical trials. Pre-clinical and development clinical development of the Company's product candidates coul
Slide 30: Specific Risks - ii
Specific Risks - ii Reliance on The responsibility of overseeing the day-to-day operations and the strategic key personnel management of the Company depends substantially on its senior management and its key personnel. There can be no assurance given that there will be no detrimental impact on the C
Slide 31: Specific Risks - iii
Specific Risks - iii Currency risk Revenue and expenditure in overseas jurisdictions are subject to the risk of fluctuations in foreign exchange markets. The Company carries on part of its business outside of Australia and intends to continue to do so. Accordingly, revenues and payments will be made
Slide 32: General Risks - i
General Risks - i Securities Applicants should be aware that there are risks associated with any securities investment investment. The prices at which the Company’s securities trade may be above or below the issue price, and may fluctuate in response to a number of factors. There can be no assurance
Slide 33: General Risks - ii
General Risks - ii Underwriting The Company has entered into an Underwriting Agreement under which the risk underwriters have agreed to fully underwrite the Rights Issue, subject to the terms and conditions of the Underwriting Agreement. If certain conditions are not satisfied or certain events occu
Slide 34: General Risks - iii
General Risks - iii COVID-19 At the time of issue of this presentation, the COVID-19 global pandemic is having a significant and material impact on global markets and providing substantial impingement on the day-to-day operations of businesses. The pandemic may disrupt or prevent the Company from un
Slide 35: Contact
CONTACT Dr. James Campbell CEO and Managing Director +61 3 9670 3273 info@patrys.com www.patrys.com Patrys Limited (ASX:PAB)